Generating new and novel biologics
Who we are
We are scientists, researchers, investors and development specialists located across Europe. We come up with new approaches for addressing today and tomorrow’s health issues—focusing on personalized medicines. We develop our innovative biologics for a personalized medicine strategy for which companion diagnostics are available leveraging our core R&D expertise to advance science.
We don’t just focus on treating illness, but also improving quality of life and improving society and scientific understanding.
Part of Polish Biotechnology
Over the last decade a new a biotechnology sector has been created almost from scratch in Poland. Through consistent investment, not only in laboratories and production lines, but also in know-how, it has driven the growth of highly-qualified jobs, as well as developed cooperation between science and business.
JJP Biologics is a new member to this growing biotechnology sector, led by specialists drawn from leading global pharmaceutical companies. We have invested significantly in supporting research and development carried out in Poland and contribute through collaborations with universities, pharmaceutical companies, industries and other drug developers.
JJP Biologics closely cooperates with research centres and universities across Poland to advance innovative research. At JJP Biologics, we are one of the few companies developing truly innovative biologics, that will advance science and improve patient outcomes.
Collaboration
To ensure our efforts have the biggest impact we collaborate with peers, academics, clinical experts, front-line health professionals, governments and advocacy groups. This focuses our efforts on the things that truly make a difference to patient outcomes and experience.
Innovation
Research and innovation is the bedrock of our business. We advance leading-edge science through a dynamic and collaborative approach. This enables us to find better solutions for treating the world’s most challenging diseases. We focus on discovering, developing and delivering drugs in therapeutic areas where we have proven expertise—and can make an impact. This is mainly focused around immunology, inflammation and oncology.
Our Pipeline & Portfolio
We develop innovative biologics for which companion diagnostics are available to enable a personalized medicine strategy.
Companion diagnostics are diagnostic tests used to check whether a therapeutic drug will be applicable and effective in a specific patient. These diagnostics detect the presence of a biomarker, that is associated with disease severity and related to the disease pathology.
We aim to progress our programs to proof-of-concept studies in the clinic. If you are interested in our programs please contact us.
Leadership
At JJP Biologics, our commitment to excellence begins at the top. With decades of combined experience in the development, manufacture and commercialization of biopharmaceuticals, a solid foundation is provided for novel therapeutic approaches. Our international management team brings both knowledge and passion to every program.
Dr Louis Boon - CSO, Management Board Member
Louis is the CSO and Management Board Member of JJP Biologics. Louis obtained his Ph.D. in Biochemistry at the University of Amsterdam. He was founder of various companies focused around the generation and development therapeutic monoclonal antibodies, primarily in the field of cancer and inflammation. In 2003, he was one of the founders of Bioceros BV, now Polpharma Biologics, where he currently holds the position of Principle Scientific Advisor. In addition, he held positions as CSO for MacroZyme BV, 4AZA Bioscience NV, FF Pharma and VP preclinical for PanGenetics BV and Tanox. Louis is an author of over 390 publications in international scientific journals in the field of medical biotechnology and an inventor at more than 20 patent applications.
Pawel Szczepanski - CEO, Management Board Member
Paweł is the CEO and Management Board Member of JJP Biologics. Involved in the biopharmaceutical market since 2014 as Supervisory Board Member of Polpharma Biologics Warsaw. Paweł has built experience in the pharmaceutical industry since 2010. First in a pharma-specialized advisory and market research house and subsequently in various capacities in Polpharma, including Director of Corporate Project Office. Prior to that has worked for six years in investment banking and management consulting in Portugal and Poland. Paweł also serves as a Supervisory Board member of Herbapol Lublin. Paweł graduated from the Warsaw School of Economics (MSc) and holds a master’s degree in law from the Warsaw University.
Scientific Advisory Board
Our advisory board brings immense expertise with international experience in the development of novel biologics.
Dr Joerg Windisch
Dr. Joerg Windisch is a seasoned executive and industrial scientist with 30 years of experience in biological medicines in the field drug development, regulatory affairs (EMA and FDA), manufacturing, quality, program management and general leadership of biotech and pharma companies. He has brought various types of biological medicines from project initiation all the way to the market in Europe, the US, and other countries.
He currently serves on the supervisory boards of several biotech companies and also runs his own consultancy firm specializing in drug development. Previously, Dr. Windisch was the CEO of Polpharma Biologics, leading the company towards FDA and EMA approvals of its first monoclonal antibody. Before this, Dr Windisch served as the COO for Affimed, a NASDAQ-traded biotech company which develops innovative bi- and tri-specific antibodies as immune cell engagers to treat various cancer types. During his 20-year tenure at Sandoz and Novartis, Dr. Windisch was a key leader in developing and obtaining approval for the first biosimilar medicines ever.
Dr. Windisch holds a Ph.D. in biochemistry, has published widely in the field, and is an inventor on many patents.
LinkedIn profile: (79) Dr. Jörg Windisch | LinkedIn
Prof. Marjolein van Egmond
Marjolein is currently Professor Oncology and Inflammation at Amsterdam UMC, location VU University Medical Center (VUmc). Her laboratory studies antibody activation of innate myeloid immune cells, macrophages and neutrophils, with emphasis on understanding the role of immunoglobulin A (IgA) in physiology and pathology. Her groups research focuses specifically on (1) the contribution of abnormal antibody responses to chronic inflammation and autoimmunity – (2) monoclonal antibody therapy of cancer. Dr. van Egmond’s research is highly translational and she is cross appointment with the Department of Surgery and the Department of Molecular Cell Biology and Immunology, to facilitate the rapid progression of pre-clinical findings into clinical applications.
Prof. Wiesław W. Jędrzejczak
MD is the head of the Department of Hematology, Transplantology and Internal Medicine at the Medical University of Warsaw. He is the Chairman of the Committee for Immunology and Etiology of Human Infections at the Polish Academy of Sciences. He specializes in internal diseases, hematology, clinical oncology and transplantology. For many years, Prof. Jędrzejczak was a national consultant in the field of hematology. His professional and scientific career is mainly connected to research related to hematopoietic stem cells and cytokines.
Prof. Jędrzejczak is one of the pioneers of chemotherapy in Poland.He discovered the first disease entity known in the medical world caused by a congenital lack of a cytokine (Macrophage Colony Stimulating Factor). As early as 1984, he and his team performed the first allogeneic marrow transplant in Poland. A year later, he carried out the first autologous transplant. Since then, he has performed over 1,000 such procedures. Prof. Jędrzejczak remains the undisputed authority in the field of clinical research regarding new drugs for the treatment of blood diseases. He has authored over 300 publications in renowned scientific journals.
Dr. Bout Bram
Dr. Bout Bram is a seasoned professional with over 30 years of experience in the biotech industry, holding both executive and supervisory positions. He served as a member of the Supervisory Boards of Polpharma Biologics (Utrecht) from 2020 to 2022 and Fibriant (Leiden) from 2023 to 2024. Prior to that, he was Chief Executive Officer and Managing Director of Bioceros from 2007 to 2019, where he led the company’s transformation into a CRO and product development powerhouse.
Additionally, Bram held the role of Chief Technology Officer at ProFibrix BV (Leiden, The Netherlands) from 2007 to 2014. Before joining Bioceros, he spent over a decade at Crucell (1993–2007), taking on increasingly senior management roles, culminating in his position as Vice President of Protein Production. He is a co-inventor of the human PER.C6® platform, a groundbreaking technology used for manufacturing vaccines, therapeutic proteins, and gene therapy products.
Dr. Bout earned his Ph.D. in Biochemistry from the University of Amsterdam.
Dr. Adi Hoess, MD, PhD
Dr. Adi Hoess, MD, PhD is an expert in immuno-oncology, autoimmune diseases, rare diseases, sustainable business model building, scientific & development strategy and business development.
Dr. Hoess is a recognized leader in innate immunity and immuno-oncology with 25+ years of biotech leadership. As CEO of Affimed, he led the transformation from an early-stage preclinical company to a Nasdaq-listed clinical innovator, securing major alliances with Genentech, J&J, Roche, and Merck. He previously led Jerini’s launch of Firazyr®, contributing to its acquisition by Shire. Earlier roles include General Manager at Carl Zeiss and co-founding MorphoSys, where he drove BD strategy and execution. Currently CEO of ViaNautis Bio. He continues to shape innovation in targeted genetic medicines.
Dr. Hoess holds an MD from TU Munich and a PhD in chemistry and biochemistry from the University of Munich, with post-doctoral training at Harvard Medical School’s Dana-Farber Cancer Institute.
Dr. Arnoud Dijkstra, PhD
After having spent 14 years in the Basel pharma industry, with his career ranging from research management in antibacterial R&D at Hoffmann-La Roche to business development and investor relations for Actelion, dr. Dijkstra moved back to the Netherlands in 2006, joining the antibody company PanGenetics as Chief Business Officer until it was sold to Abbott. He then was CBO of the haemostasis company Profibrix, which was acquired by The Medicines Company, after which he held management positions in several other private biotech companies, including Staten Biotechnology and VarmX. He currently provides consultancy services in the field of financing and business development and is also a Venture Partner at BioGeneration Ventures.
Dr. Dijkstra holds a MSc in chemistry and a PhD in Biochemistry from Groningen University.